Find a Clinical Trial

Showing 201 - 210 of 225 Trials

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT05462717

Population:

Adult

Phase:

I

The purpose of this study is to test a new drug called RMC-6291, to evaluate its safety at different doses, and to find out how the body processes it. RMC-6291 is a new experimental drug, which means that it is not approved by the US Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC- 6291 will be tested in humans. Are you Eligible? (Inclusion Criteria) Must be 18 year old or older - Life expectancy of more than 3 months - Subjects must be able to take the study drug and retain by mouth
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT05627245

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of drugs called tazemetostat and belinostat when administered together. This study tests different doses of the drugs to see which doses are safer for people. There will be between 21 and 48 people taking part in this study. There are two parts in this study, a dose escalation (dose finding) part and a dose expansion part (where the established dose is tested further). In the dose escalation part of this study, different people will get different doses of the study drugs tazemetostat and belinostat. The first 3 people taking part in this study...
Phase I trial of ZEN003694 (ZEN-3694) in combination with capecitabine in patients with solid tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05803382

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of a drug called ZEN003694 (ZEN-3694), in combination with the usual approach of capecitabine. This study tests different doses of ZEN003694 in combination with capecitabine to see which dose is safer for people. There will be between 21 and 30 people taking part in this study. This drug combination is not approved by the FDA for treatment of the disease being studied. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Have you been diagnosed with metastatic or unresectable cancer, which progressed while you were treated...
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT04855656

Population:

Adult

Phase:

I

The purpose of this research study is to test how safe RP-6306 is at different doses and schedules, test how well RP-6306 works to shrink cancer in the body, and evaluate if food affects the way RP-6306 moves through your body. This study will test the investigational drug, RP-6306, for the first time in humans. “Investigational” means that the study drug being tested has not been approved by the United States Food and Drug Administration (FDA). RP- 6306 is a PKMYT1 inhibitor (blocks the activity of the PKMYT1 protein) that is designed to stop certain cancer cells from growing...
Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics ofASKG915 as a Single Agent in Patients with Selected Advanced Solid Tumors

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT05867420

Population:

Adult

Phase:

I

The purpose of this study is to test the safety and effectiveness of ASKG915 at different dose levels to find out what effects, good or bad, this study drug has on you and your cancer. ASKG915 is an experimental treatment that is being developed for treating people with advanced solid tumors. “Experimental” means the study drug has not been approved for the treatment of participants with cancer by the Food and Drug Administration (“FDA”) or any other health/regulatory authority anywhere in the world. This is the first time ASKG915 is being tested in humans. Are you...
Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT02303821

Population:

Pediatrics

Phase:

I

The purpose of this study is to learn more about the treatment of children and teenagers whose leukemia has come back (has relapsed) or has not gone away after other treatments (is refractory). Participants will receive the study drug, called carfilzomib in combination with standard chemotherapy, that are dexamethasone, daunorubicin , vincristine and PEG-asparaginase (VXLD backbone). The study consist of 4 periods: Screening Period, Treatment Period, End of Study Period, and Long-term Follow-up Period. Participants with stable disease or better response at the end of the Induction Cycle will...
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 inCombination With FOLFIRI for the Treatment of AdvancedSolid Tumors (MINOTAUR Study)

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05147350

Population:

Adult

Phase:

I

The purpose of this study is to test how safe RP-6306 and FOLFIRI are when given together at different doses and on different schedules, and test how well RP-6306 and FOLFIRI work together to shrink solid tumors in the body. This is the first time RP-6306 is being given with FOLFIRI to humans. Are you Eligible? (Inclusion Criteria) ≥18 years old have locally advanced or metastatic CRC, GI, or esophageal cancer(s) Life expectancy ≥12 weeks able to swallow oral medications
R5458-ONC-2012:PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTICD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Principal Investigator:

Rajshekar Chakraborty, MD

Contact Number:

212-342-5162

NCT Number:

NCT05137054

Population:

Adult

Phase:

I

This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? - Are you likely to live for at least six more months? -Do you have measurable disease as defined in the protocol according to International Myeloma Working Group (IMWG)...
SL03-OHD-105: An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05483933

Population:

Adult

Phase:

I

The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian cancer. The study drug, SL-172154 is an immunotherapy drug. Immunotherapies are treatments that use your body’s own immune (defense) system to help fight cancer. SL-172154 binds to a protein called CD47 on cancer cells and to a protein called CD40 on immune...
A NON-RANDOMIZED PROSPECTIVE CLINICAL TRIAL COMPARING THE NON-INFERIORITY OF SALPINGECTOMY TO SALPINGO-OOPHORECTOMY TO REDUCE THE RISK OF OVARIAN CANCER AMONG BRCA1 CARRIERS [SOROCk]

Principal Investigator:

Jason D. Wright, MD

Contact Number:

212-342-5162

NCT Number:

NCT04251052

Population:

Adult

Phase:

NA

The main purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for ovarian cancer risk reduction in women with BRCA1 mutations who have completed childbearing. In this study, the removal of fallopian tubes will be compared to the removal of fallopian tubes and ovaries. The study will also examine what factors go into deciding which surgery to have and symptoms after surgery caused by...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages